Assessment of interactions between cisplatin and two histone deacetylase inhibitors in MCF7, T47D and MDA-MB-231 human breast cancer cell lines - An isobolographic analysis

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Wawruszak, Anna ^a   Luszczki, Jarogniew J ^a,b   Grabarska, Aneta ^a   Gumbarewicz, Ewelina ^a   Dmoszynska Graniczka, Magdalena ^a   Polberg, Krzysztof ^c   Stepulak, Andrzej ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c MSW Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ANALYSIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC50; ISOBOLOGRAPHIC ANALYSIS; MONOTHERAPY; CELL CYCLE CHECKPOINT; COMBINATION DRUG THERAPY; DRUG EFFECTS; FEMALE; MCF-7 CELL LINE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; VALPROIC ACID;

EID: 84957900601     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143013     Document Type: Article

References (74)

1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available: Http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx.
2. Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother. 2015; 16: 983-998. PMID: 25881743
3. Dawood S, Broglio K, Gonzalez-Angulo AM. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol. 2008; 26: 4891-4898. doi: 10.1200/JCO.2007.14.1168 PMID: 18725649
4. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2015; 33: 1902-1909. doi: 10.1200/JCO.2014.57.6660 PMID: 25847936
5. Viet C, Dang D, Achdjian S, Ye Y, Katz S, Schmidt B. Decitabine Rescues Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma. PLoS One. 2014 Nov 12; 9(11).
6. Denis I, Cellerin L, Gregoire M, Blanquart C. Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma. Oncotarget. 2014; 5: 11641-11652. PMID: 25361002
7. Mann B, Johnson J, Cohen M, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007; 12: 1247-1252. PMID: 17962618
8. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008; 49: 502-507. doi: 10.1080/10428190701817258 PMID: 18297527
9. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda W, et at. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008; 111: 1060-1066. PMID: 17962510
10. Galanis E, Jaeckle K, Maurer M, Reid J, Ames M, Hardwick J, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: A north central cancer treatment group study. J Clin Oncol. 2009; 27: 2052-2058. doi: 10.1200/JCO.2008.19.0694 PMID: 19307505
11. Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker J, Randolph S, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs. 2006; 26: 483-488.
12. Modesitt S, Sill M, Hoffman J, Bender D. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2008; 109: 182-186. doi: 10.1016/j.ygyno.2008.01.009 PMID: 18295319
13. Blaheta R, Cinatl J Jr. Anti-tumor mechanisms of valproate: A novel role for an old drug. Med Res Rev. 2002; 22: 492-511. PMID: 12210556
14. Lakshmaiah K, Jacob LA, Aparna S, Lokanatha D, Saldanha S. Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther. 2014; 10: 469-478. doi: 10.4103/0973-1482.137937 PMID: 25313724
15. Xu W, Parmigiani R, Marks P. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene. 2007; 26: 5541-5552. PMID: 17694093
16. Heerboth S, Lapinska K, Snyder N, Leary M, Rollinson S, Sarkar S. Use of Epigenetic Drugs in Disease: An Overview. Genet Epigenet. 2014; 6: 9-19. doi: 10.4137/GEG.S12270 PMID: 25512710
17. Hiriyan J, Shivarudraiah P, Gavara G, Annamalai P, Natesan S, Sambasivam G, et al. Discovery of PAT-1102, a Novel, Potent and Orally Active Histone Deacetylase Inhibitor with Antitumor Activity in Cancer Mouse Models. Anticancer Res. 2014; 35: 229-237.
18. Dodurga Y, Gundogdu G, Tekin V, Koc T, Satiroglu-Tufan NL, Bagci G, et al. Valproic acid inhibits the proliferation of SHSY5Y neuroblastoma cancer cells by downregulating URG4/URGCP and CCND1 gene expression. Mol Biol Rep. 2014; 41: 4595-4599. doi: 10.1007/s11033-014-3330-3 PMID: 24652203
19. Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M, Rodriguez R. Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J Biomed Biotechnol. 2012; 2012: 180363. doi: 10.1155/2012/180363 PMID: 23093837
20. Travaglini L, Vian L, Billi M, Grignani F, Nervi C. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol. 2009; 41: 225-234. doi: 10.1016/j.biocel.2008.08.019 PMID: 18789398
21. Feng D, Wu J, Tian Y, Zhou H, Zhou Y, Hu W, et al. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model. PLoS One. 2013 Nov 19; 8(11).
22. Gan CP, Hamid S, Hor SY, Zain RB, Ismail SM, Wan Mustafa WM, et al. Valproic acid: Growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck. 2012; 34: 344-353. doi: 10.1002/hed.21734 PMID: 21438066
23. Shah RD, Jagtap JC, Mruthyunjaya S, Shelke GV, Pujari R, Das G, et al. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition. J Cell Biochem. 2013; 114: 854-863. doi: 10.1002/jcb.24422 PMID: 23097134
24. Zhou Y, Xu Y, Wang H, Niu J, Hou H, Jiang Y. Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro. Oncol Lett. 2014; 7: 203-208. PMID: 24348849
25. Jiang W, Zheng Y, Huang Z, Wang M, Zhang Y, Wang Z, Jin X, Xia Q. Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness. Int Urol Nephrol. 2014; 46: 941-946. doi: 10.1007/s11255-013-0609-6 PMID: 24265041
26. Sun G, Mackey LV, Coy DH, Yu CY, Sun L. The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling. J Cancer. 2015; 6: 996-1004. doi: 10.7150/jca.12135 PMID: 26366213
27. Xu Y, Xu D, Zhu SJ, Ye B, Dong JD, Zhang YL, et al. Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA). Int J Clin Exp Pathol. 2015; 8: 8291-8297. PMID: 26339399
28. Li GF, Qian TL, Li GS, Yang CX, Qin M, Huang J, et al. Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression. Genet Mol Res. 2012; 11: 77-86. doi: 10.4238/2012.January.13.1 PMID: 22290468
29. Zhang L, Wang G, Wang L, Song C, Leng Y, Wang X, et al. VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. Mol Cell Biochem. 2012; 361: 39-45. doi: 10.1007/s11010-011-1085-x PMID: 21959976
30. Vafaiyan Z, Gharaei R, Asadi J. The correlation between telomerase activity and Bax/Bcl-2 ratio in valproic acid-treated MCF-7 breast cancer cell line. Iran J Basic Med Sci. 2015; 18: 700-704. PMID: 26351561
31. Travaglini L, Vian L, Billi M, Grignani F, Nervi C. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol. 2009; 41: 225-234. doi: 10.1016/j.biocel.2008.08.019 PMID: 18789398
32. Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, Zheng HC. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One. 2013 Nov 13; 8(11)
33. Tzao C, Jin JS, Chen BH, Chung HY, Chang CC, Hsu TY, et al. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo. Dis Esophagus. 2014; 27: 693-702. doi: 10.1111/dote.12127 PMID: 24033428
34. Vijayaraghavalu S 1, Dermawan JK, Cheriyath V, Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol Pharm. 2013; 10: 337-352. doi: 10.1021/mp3004622 PMID: 23215027
35. Chiao MT, Cheng WY, Yang YC, Shen CC, Ko JL. Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy. 2013; 9: 1509-1526. doi: 10.4161/auto.25664 PMID: 23962875
36. Lee YJ, Won AJ, Lee J, Jung JH, Yoon S, Lee BM, et al. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci. 2012; 9: 881-893. doi: 10.7150/ijms.5011 PMID: 23155362
37. Sun PC, Tzao C, Chen BH, Liu CW, Yu CP, Jin JS. Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells. J Biomed Sci. 2010 17; 17: 76. doi: 10.1186/1423- 0127-17-76 PMID: 20846458
38. Yang H, Lan P, Hou Z, Guan Y, Zhang J, Xu W, et al. Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma. Br J Cancer. 2015; 112: 112-121. doi: 10.1038/bjc.2014.547 PMID: 25393367
39. Florea A, Büsselberg D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers 2011; 3: 1351-1371. doi: 10.3390/cancers3011351 PMID: 24212665
40. Greco WR, Bravo G, Parsons JC. The search for synergy: A critical review from a response surface perspective. Pharmacol Rev. 1995; 47: 331-385. PMID: 7568331
41. Litchfield J, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96: 99-113. PMID: 18152921
42. Luszczki JJ. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: A practical application. Naunyn Schmiedebergs Arch Pharmacol. 2007; 375: 105-114. PMID: 17333129
43. Luszczki JJ, Czuczwar SJ. Isobolographic profile of interactions between tiagabine and gabapentin: A preclinical study. Naunyn-Schmiedebergs Arch Pharmacol. 2004; 369: 434-446. PMID: 14985937
44. Luszczki JJ, Czuczwar SJ. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: A three-dimensional isobolographic analysis. Naunyn-Schmiedebergs Arch Pharmacol. 2006; 374: 51-64. PMID: 16972063
45. Grabovsky Y, Tallarida RJ. Isobolographic analysis for combinations of a full and partial agonist: Curved isoboles. J Pharmacol Exp Ther. 2004; 310: 981-986. PMID: 15175417
46. Tallarida RJ. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther. 2006; 319: 1-7. PMID: 16670349
47. Tallarida RJ. Interactions between drugs and occupied receptors. Pharmacol Ther. 2007; 113: 197-209. PMID: 17079019
48. Tallarida RJ. Drug synergism and dose-effect data analysis. Chapman and Hall/CRC, Boca Raton, USA; 2000.
49. Erlich R, Rickwood D, Coman W, Saunders N, Guminski A. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol. 2009; 63: 381-389. doi: 10.1007/s00280-008-0747-1 PMID: 18398612
50. Shena J, Huangb C, Jianga L, Gaoa F, Wanga Z, Zhanga Y. et al. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol. 2007; 73: 1901-1909. PMID: 17445779
51. Eastman A. The Mechanism of Action of Cisplatin: From Adducts to Apoptosis. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, Verlag Helvetica Chimica Acta, Zürich; 2009.
52. Suzuki M, Endo M, Shinohara F, Echigo S, Rikiishi H. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemother Pharmacol. 2009; 64: 1115-1122. doi: 10.1007/s00280-009-0969-x PMID: 19280190
53. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003; 63: 7291-7300. PMID: 14612526
54. Berenbaum MC. What is synergy?. Pharmacol Rev. 1989; 41; 93-141. Erratum published in Pharmacol Rev. 1989;41: 422. PMID: 2692037
55. Prater J, Valeri F, Korol D, Rohrmann S, Dehler S. Incidence of metachronous contralateral breast cancer in the Canton of Zurich: A population-based study of the cancer registry. J Cancer Res Clin Oncol. 2015 Aug 23. [Epub ahead of print].
56. Feng D, Wu J, Tian Y, Zhou H, Zhou Y, Hu W, et al. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model. PLoS One. 2013 Nov 19; 8(11).
57. Chien CW, Yao JH, Chang SY, Lee PC, Lee TC. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide. Toxicol Appl Pharmacol. 2011; 257: 59-66. doi: 10.1016/j.taap.2011.08.018 PMID: 21889949
58. Lee J, Choy M, Ngo L, Foster S, Marks P. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A. 2010; 107: 14639-14644. doi: 10.1073/pnas.1008522107 PMID: 20679231
59. Lin C, Lai H, Lee H, Lin W, Chang C, Chu T. et al. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci. 2008; 99: 1218-1226. doi: 10.1111/j.1349-7006.2008.00793.x PMID: 18429963
60. Krämer OH, Mahboobi S, Sellmer A. Drugging the HDAC6-HSP90 interplay in malignant cells. Trends Pharmacol Sci. 2014; 35: 501-509. doi: 10.1016/j.tips.2014.08.001 PMID: 25234862
61. Nighat N, Hamid R, Saima K. Identyfication of type-specific anticancer histone deacetylase inhibitors: Road to success. Cancer Chemother Pharmacol. 2010; 66: 625-633. doi: 10.1007/s00280-010-1324-y PMID: 20401613
62. Bortugno O, Santoro F, Minucci F. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett. 2009; 280: 134-144. doi: 10.1016/j.canlet.2009.02.027 PMID: 19345000
63. Fortunati N, Bertino S, Constatino L, Bosco O, Vercellinatto L, Catalano M, et al. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Letters. 2008; 259: 156-154. PMID: 18006146
64. Hirsch C, Bonham K. Histone deacetylase inhibitors regulate p21WAF1 gene expression at the posttranscriptional level in HepG2 cells. FEBS Lett. 2004; 570: 37-40. PMID: 15251435
65. Knutson A, Welsh J, Taylor T, Roy S, Wang W, Tenniswood M. Comparitive effects of histone deaceylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells. Oncol. Rep. 2010; 112: 3044-3053.
66. Pizarro A, Sadler P. Unusual DNA binding modes for metal anticancer complexes. Biochemie. 2009; 91: 1198-1211.
67. Biswas S, Huang J, Persaud S, Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther. 2004; 3: 327-334. PMID: 15026553
68. Eastman A. The Mechanism of Action of Cisplatin: From Adducts to Apoptosis. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, Verlag Helvetica Chimica Acta, Zürich; 2009.
69. Florea A, Büsselberg D. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects. Cancers 2011; 3: 1351-1371. doi: 10.3390/cancers3011351 PMID: 24212665
70. Lee J, Choy M, Ngo L, Foster S, Marks P. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci U S A. 2010; 107: 14639-14644. doi: 10.1073/pnas.1008522107 PMID: 20679231
71. Lin C, Lai H, Lee H, Lin W, Chang C, Chu T. et al. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci. 2008; 99: 1218-1226. doi: 10.1111/j.1349-7006.2008.00793.x PMID: 18429963
72. Blaheta R, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B. et al. Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Cancer. 2007; 96: 1699-1706. PMID: 17505515
73. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005; 23: 3923-3931. PMID: 15897550
74. Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab. 2005; 90: 1383-1389. PMID: 15585556